Loading stock data…
$18.37-0.62 (-3.26%)
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally.
Enovis Corporation in the Healthcare sector is trading at $18.37 with a market capitalization of $1.1B. Wall Street consensus targets $36.08 (12 analysts), implying a +96.4% move over the next 12 months. The stock is currently near its 52-week low of $16.70, remaining 21.6% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $582.78M↓ | $589.15M↑ | $575.76M↑ | $548.91M↓ | $564.54M |
| Gross Profit | $359.25M↓ | $365.49M↑ | $349.42M↑ | $328.91M↓ | $334.70M |
| Operating Income | $22.27M↑ | $9.24M↓ | $48.25M↑ | -$8.14M↑ | -$16.08M |
| Net Income | -$1.19M↑ | -$8.76M↑ | -$520.59M↑ | -$571.15M↓ | -$36.74M |
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Preventi...